Bayer and Fujifilm scored exits as the cancer treatment developer floated on the Nasdaq Global Select Market at the top of its range.

Century Therapeutics, a US-based cancer immunotherapy developer backed by pharmaceutical and chemical group Bayer and optics and medical engineering group Fujifilm, has gone public in a $211m initial public offering. The company issued 10.6 million shares on the Nasdaq Global Select Market priced at $20 per share, which was the upper end of the offering’s…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.